Hepatitis C

Current Opinion in Infectious Diseases

Volumn 11, Issue 3, 1998, Pages 293-299

  Jenny Avital, Elizabeth R ^a  

^a JACOBI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; RIBAVIRIN;

AGE; ALCOHOL CONSUMPTION; CELLULAR IMMUNITY; CHRONIC LIVER DISEASE; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; HEPATITIS C; HUMAN; IMMUNE STATUS; LIVER INJURY; REVIEW; SEX DIFFERENCE; T LYMPHOCYTE; VIRUS LOAD;

EID: 0031865071     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199806000-00005     Document Type: Review

References (62)

1. Choo Q, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244:359-361. A very important piece of work elegantly describing the novel way in which a new virus and the diagnostic test for that virus was discovered.
2. Lok ASF, Gunaratnam NT. Diagnosis of hepatitis C. Hepatology 1997; 26:48S-56S.
3. Schmidt WN, Wu P, Cederna J, Mitros FA, LaBrecque DR, Stapleton JT. Surreptitious hepatitis C virus (HCV) infection detected in the majority of patients with cryptogenic chronic hepatitis and negative HCV antibody tests. J Infect Dis 1997; 179:27-33.
4. Major M, Feinstone S. The molecular virology of hepatitis C. Hepatology 1997; 25:1527-1538. A comprehensive review of the structural and functional organization of the HCV genome.
5. Zibert A, Eckart S, Roggendorf M. Antibodies to human sera specific to hypervariable region-1 of hepatitis C virus can block viral attachment. Virology 1995; 208:653-661.
6. Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994; 91:7792-7796.
7. Kato N, Sekiya H, Ootsuyama Y, Nakazawa T, Hijikata M, Ohkoshi S, Shimotohno K. Humoral immune response to hypervariable region-1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol 1993; 67:3923-3930.
8. Gonzalez-Peralta RP, Quian K, She JY, Davis GL, Ohno T, Mizokami M, Lau JYN. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C. J Med Virol 1996; 49:242-247.
9. Farci P, Melpolder JC, Shimoda A, Peddis G, Strazzera A, Munoz S, et al. Studies of HCV quasispecies in patients with acute resolving hepatitis compared to those who progress to chronic hepatitis. Hepatology 1996; 24:350A.
10. Kumar U, Monjardino J, Thomas HC. Hypervanable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Gastroenterology 1994; 106:1072-1075.
11. Guadagnino V, Stroffolini T, Rapicetta M, Constantino A, Kondili LA, Menniti-Ipolito F, et al. Prevalence, risk factors and genotype distribution of hepatitis C virus infection in the general population: a community based survey in southern Italy. Hepatology 1997; 26:1006-1011.
12. Noguchi S, Sata M, Suzuki H, Mizokami M, Tanikawa K. Routes of transmission of hepatitis C virus in an endemic rural area in Japan: molecular epidemiologic study of hepatitis C virus infection. Scand J Infect Dis 1997; 29:23-28.
13. Prati D, Capelli C, Silvani C, DeMattei C, Bosoni P, Pappalettera M, et al. Incidence and risk factors of community acquired hepatitis in a cohort of Italian blood donors. Hepatology 1997; 25:702-704.
14. Bronowicki JP, Venard V, Botte C, Monhoven N, Gastin I, Chone L, et al. Patient to patient transmission of hepatitis C virus during colonoscopy. N Eng J Med 1997; 337:237-240. Contains an excellent and eye-opening discussion of the magnitude of the problem of nosocomial transmission of blood-borne pathogens.
15. Alter HJ, Conry-Cantilena C, Melpolder J, Tan D, Van Raden M, Herion D, et al. Hepatitis C in symptomatic blood donors. Hepatology 1997; 26 (Suppl 1):29S-33S. By identifying cocaine as an important risk factor for HCV infection in the USA and linking that to inapparent percutaneous exposure, Dr Alter gives clinicians an important insight into HCV transmission. Equally important, this article showed how careful history taking can ellicit important historical information that is overlooked by more superficial questioning.
16. Dienstag J. Sexual and perinatal transmission of hepatitis C. Hepatology 1997; 26 (Suppl 1):66S-70S. A very comprehensive review that provides important data on which recommendations to patients can be based.
17. Power JP, Davidson F, O'Riordan J, Simmonds P, Yap PL, Lawlor E. Hepatitis C infection from anti-D immunoglobulin [letter]. Lancet 1995; 346:372-373.
18. Thomas DL, Zenilman JM, Alter HJ, Shih JW, Galai N, Carella AV, Quinn TC. Sexual transmission of hepatitis C virus among patients attending a sexually disease clinic in Baltimore-analysis of 309 sex partnerships. J Infect Dis 1995; 171:768-775.
19. Arthur RR, Hassan NF, Abdallah MY, El-Sharkawy MS, Saad MD, Hackbart BG, Imam IZ. Hepatitis C antibody prevalence in blood donors in different governorates in Egypt. Trans R Soc Trop Med Hyg 1997; 91:271-274.
20. Tibbs CJ, Royal Society of Tropical Medicine and Hygiene meeting at Mansion House, London, 16 May 1996. Tropical aspects of viral hepatitis - hepatitis C. Trans R Soc Trop Med Hyg 1997; 91:121-124. Provides very interesting insights into potential mechanisms accounting for high transmission rates of HCV in tropical settings.
21. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mon C, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the antiviral cell mediated immune response. J Clin Invest 1996; 98:706-714.
22. Zibert A, Meisel H, Kraas W, Schulz A, Jung G, Roggendorf M. Early antibody response against hypervariable region 1 is associated with acute self limiting infections of hepatitis C virus. Hepatology 1997; 25:1245-1249.
23. Lechmann M, Ihlenfeldt HG, Braunschweiger I, Giers G, Gunther J, Matz B, et al. T-and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus-positive blood donors without viremia. Hepatology 1996; 24:790-795.
24. Thiele DL, Ducharme L, Cunningham MR. Steroid therapy of chronic hepatitis: characteristics associated with response in anti-hepatitis C virus-positive and -negative patients. Am J Gastroenterol 1996; 91:300-308.
25. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, et al. Ribavirin as therapy for chronic hepatitis C: a randomized double blind placebo-controlled trial. Ann Intern Med 1995; 123:897-903.
26. Mihm S, Fayyazi A, Ramadori G. Hepatic expression of inducible nitric oxide sythase transcripts in chronic hepatitis C virus infection: relation to hepatic viral load and liver injury. Hepatology 1997; 26:451-458.
27. Shiffman ML, Hofmann CM, Thompson EB, Ferreira-Gonzalez A, Contos MJ, Koshy A, et al. Relationship between biochemical, virological and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997; 26:780-785.
28. Nelson DR, Marousis CG, Davis GL, Rice CM, Wong J, Houghton M, Johnson YNL. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997; 158:1473-1481.
29. Gonzalez-Peralta RP, Fang JWS, Davis GL, Gish RG, Wu PC, Mizokami M, Lau JYN. Immunopathobiology of chronic hepatitis C virus infection. Hepatology 1994; 20:232A.
30. Chang KM, Rehermann B, Chisari FV. Immunopathology of hepatitis C. Springer Semin Immunopathol 1997; 19:57-68.
31. Asanza CG, Garcia-Monzon C, Clemente G, Salcedo M, Garcia-Buey L, Garcia-Iglesias C, et al. Immunohistochemical evidence of immunopathogenetic mechanisms in chronic hepatitis C recurrence after liver transplantation. Hepatology 1997; 26:755-763.
32. Seeff L. Natural history of hepatitis C. Hepatology 1997; 26 (Suppl 1):21S-28S. A very lucid description of the natural history studies to date in HCV.
33. Tong M, El-Farra N. Clinical sequelae of hepatitis C acquired from injection drug use. West J Med 1996; 164:399-404.
34. Crowe J, Doyle C, Fielding JF, Holloway H, Keegan M, Kelleher D, et al. Presentation of hepatitis C in a unique cohort 17 years form inoculation [abstract]. Gastroenterology 1995; 108:1054A.
35. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, et al. and the National Heart, Lung, and Blood Institute Study Group. Long-term mortality after transfusion associated non-A, non-B hepatitis. N Engl J Med 1992; 327:1906-1911.
36. Poynard T, Bedossa P, Opolon P for the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349:825-832. An important contribution to the natural history of HCV literature.
37. Kage M, Shimamatu K, Nakashima E, Masamichi K, Inoue O, Yano M. Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C: morphometric analysis of repeated biopsies. Hepatology 1997; 25:1028-1031.
38. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D and the Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6664 patients. Hepatology 1997; 26:485-490.
39. Serfaty L, Chazouilleres O, Poujol-Robert A, Morand-Joubert L, Dubois C, Chretien Y, et al. Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: results of a case-control study. Hepatology 1997; 26:776-779.
40. Vargas HE, Wang LF, Laskus T, Poutous A, Lee R, Demetris A, et al. Distribution of infecting hepatitis C genotypes in end-stage liver disease patients at a large American transplantation center. J Infect Dis 1997; 175:448-450.
41. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immunoglobulin. N Engl J Med 1994; 331:1607-1611.
42. Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengoechea M, Herandez-Quero J, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26:1-5.
43. Rossi G, Tucci A, Cariani E, Ravaggi A, Rossini A, Rodaeli E. Outbreak of hepatitis C virus infection in patients with hematologic disorders treated with intravenous immunoglobulins: dfferent prognosis according to immune status. Blood 1997; 90:1309-1314.
44. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ for the Multicenter Hemophilia Cohort Study. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Blood 1994; 84:1020-1023.
45. Jenny-Avital E. [abstract]. Outcome of dual HIV-Hepatitis C (Hep C) infection. Clin Infect Dis 1997; 25:373.
46. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghirozi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1997; 338:286-290. A very clinically important observation with implications for clinical intervention.
47. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR 1996; 45:1-3.
48. Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328:465-470.
49. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327:1490-1495.
50. Zuckerman E, Zuckerman T, Levine AM, Douer D, Gutekunst K, Mizokami M, et al. Hepatitis C infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med 1997; 127:423-428.
51. Zehender G, Merani L, De Maddalena C, Varchetta S, Mont G, Galli M. Detection of hepatitis C virus RNA in CD 19 peripheral blood mononuclear cells of chronically infected patients. J Infect Dis 1997; 176:1209-1214.
52. Hoofnagle JH, Mullen KD, Jones DB, Rostgi V, Di Bisceglie A, Peters M, Waggoner JG. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med 1986; 315:1575-1578.
53. Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Leefe EB, et al. and the Consensus Interferon Study Group. Treatment of chronic hepatitis C with consensus interferon: a multicenter randomized, controlled trial. Hepatology 1997; 26:747-754.
54. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23:1334-1340
55. Poynard T, Leroy V, Cohard M, Thiermot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effect of dose and duration. Hepatology 1996; 24:778-789.
56. Manesis EK, Papioannou C, Gioustozi A, Kafiri G, Kosinas J, Hadziyannis SJ. Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4 year follow-up of 211 patients. Hepatology 1997; 26:734-739.
57. Picciotto A, Campo N, Brizzolara R, Sinelli N, Poggi G, Grasso S, Celle G. HCV-RNA levels play an important role independently of genotype in predicting response to interferon therapy. Eur J Gastroenterol Hepatol 1997; 9:67-69.
58. Ballardini G, Manzin A, Giostra F, Francesconi R, Groff P, Grassi A, et al. Quantitative liver parameters of HCV infection: relation to HCV genotypes, viremia, and response to interferon. J Hepatol 1997; 26:779-786.
59. Tsubota A, Kumada H, Chayama K, Arase Y, Saitoh S, Koida I, et al. Time-course of histological changes in patients with a sustained biochemical and virological response to interferon-alpha therapy for chronic hepatitis C infection. J Hepatol 1997; 27:49-55.
60. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg, Weiland O for the Swedish Study Group. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351:83-87. Likely a forerunner of many important trials to come.
61. Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan PW, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111:1307-1312.
62. Noguchi S, Michio S, Suzuki H, Ohba K, Massahi M, Tanikawa K. Early interferon for acute hepatitis C acquired through a needlestick. Clin Infect Dis 1997; 24:992-994.